Huapont In-Licenses China Rights to Histogen's Stem Cell Hair Growth Injections

Huapont Life Sciences of Chongqing in-licensed China rights to an injectible stem cell-based hair regrowth product being developed by San Diego's Histogen. One month ago, Huapoint, though its Pinewood Capital division, made an $6 million investment in Histogen. The investment was part of a D round that expects to raise $18 million.To secure the rights, Huapoint agreed to pay milestones, a transfer price on the product and escalating royalties on sales. More details.... Stock Symbol: (SHA: 002004) Share this with colleagues: // //